Rutherford-based Cancer Genetics Inc., an oncology research company, announced Monday that Panna Sharma has stepped down as CEO, president and director of the company.
The company’s board has named John A. “Jay” Roberts, currently the chief operating officer, as interim CEO.
“I would like to thank the board, our partners and collaborators, and most of all our employees and teams across the world for the numerous achievements that have built this into a global, leading company in the precision oncology arena,” Sharma said. “I am confident in their commitment to innovation and the future of personalized medicine.”
Sharma, the company said, will provide consulting services to assist with the transition.
“We would like to thank Panna for his service and contributions to Cancer Genetics and his leadership through our evolution and growth as a company. We are confident of a seamless transition and the continued operational progress being made by the business,” said John Pappajohn, chairman of the board. “We wish him well in his future endeavors.
“Jay has been a member of the management team at Cancer Genetics since July 2016 as chief operating officer. He has in-depth familiarity with our business and growth strategy, and a long and successful health care industry career. With Jay as interim CEO, the company will have a seamless transition that will allow us to continue on our strategic path and maintain our growth in the biopharma arena as we move towards profitability. Jay will be supported by our chief medical officer, Dr. Rita Shaknovich … and a strong financial team.”
